inflammatory potential of 2-styrylchromones regarding their interference with arachidonic acid metabolic pathways.
Arachidonic acid is the most abundant polyunsaturated fatty acid in the phospholipid bilayer of cell membranes. This second-messenger molecule is released by phospholipase A 2 in activated cells and further metabolized in different eicosanoids by the cyclooxygenase and lipoxygenase pathways ( Fig. 1 ). Cyclooxygenases (COXs) are the key enzymes in the biosynthesis of prostanoids. In mammalian cells, COXs exist in at least two isoforms (COX-1 and COX-2).
COX-1 is a constitutive enzyme, expressed in almost every cell type, responsible for the physiological production of prostaglandins (PGs) i.e., PGI 2 , PGE 2 , PGF 2α , and PGD 2 , in diverse organs and thromboxane A 2 in platelets. COX-2, on the other hand, is usually absent in most tissues (with the exception of kidney, parts of the brain, and gravid uterus where COX-2 is constitutive) but its expression can be readily induced by numerous stimuli like such as growth factors, tumor promoters, or cytokines [1, 2] . The earliest expression of COX-2 is detected in stromal cells, but it also can be found in multiple cells, like epithelial, endothelial, and stromal cells in several types of tumors [3] . In addition, COX-2 is highly expressed by cells that are involved in inflammation (e.g., neutrophils, macrophages, monocytes, mast cells, synoviocytes), emerging as the isoform primarily responsible for the synthesis of the prostanoids involved in pathological processes, such as acute and chronic inflammatory states. These inflammationrelated cell types can be stimulated by lipopolysaccharide, phorbol esters, cytokines, or growth factors, producing large amounts of PGs, in particular PGE 2 and PGI 2 , which are pro-4 inflammatory mediators that increase vascular permeability and promote edema at the sites of inflammation. Furthermore, these PGs are involved in the nociception of the inflammatory pain [4] . Thus, COX-2 isoform has been associated with acute and chronic inflammatory disorders [5] as well as in the carcinogenesis and tumor progression [3] .
Lipoxygenases (LOXs) are enzymes that produce hydroxy acids and leukotrienes (LTs). From the LOXs existent in the mammalian tissues, 5-LOX, which is mainly found in cells of myeloid origin, i.e., polymorphonuclear leukocytes (PMNL), mast cells, macrophages, is the most implicated in inflammatory and allergical disorders [6] . 5-LOX metabolizes arachidonic acid to yield 5(S)-hydroxy-6,8,11,14-eicosatetraenoic acid (5-HETE), which is further metabolized to the bioactive 5-oxo-6,8,11,14-eicosatetraenoic acid (5-oxo-ETE) by PMNL 5-hydroxyeicosanoid dehydrogenase [7] , and various LTs (LTA 4 -LTE 4 ) [8] . 5-oxo-ETE and LTB 4 , produced by PMNL, are potent chemoattractant mediators of inflammation. LTB 4 stimulates neutrophil chemotaxis, enhances neutrophil-endothelial interactions, and stimulates neutrophil activation, leading to degranulation and the release of mediators, enzymes, and superoxide radicals [9] , while 5-oxo-ETE is much more active than LTB 4 as an eosinophil chemoattractant [10] . LTC 4 , LTD 4 and LTE 4 , also known as Cys-leukotrienes, have shown to be essential mediators in asthma pathophysiology [11] .
Although the major pathophysiological implication of LTs was considered to be the bronchial asthma, these eicosanoids contribute to the pathogenesis of other human inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease, Crohn's disease, and psoriasis (see [11] [12] [13] for reviews). Recently, the 5-LOX pathway has also been associated with atherosclerosis, osteoporosis and certain types of cancer like prostate cancer [12] . M a n u s c r i p t 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65   5 Non-steroidal anti-inflammatory drugs (NSAIDs) are the most commonly used remedy in inflammatory disorders. However, they cause several adverse effects, the most important being gastric injury up to gastric ulceration, renal failure and asthma [14] . On the other hand, the COX-2 selective drugs, generically known as COXIBs, have recently been a cause of controversy due to the enhanced cardiovascular risk they carry [13] . Thus, alternative therapeutic solutions, with similar anti-inflammatory potency but with fewer side effects, are needed, especially for the control of chronic inflammatory diseases, which implicate longer therapies.
2-Styrylchromones (2-SC) are a chemical family of oxygen heterocyclic compounds, vinylogues of flavones (2-phenylchromones), whose occurrence in nature has been reported [15, 16] . Natural and synthetic 2-styrylchromones have been tested in different chemical and biological systems, showing activities with potential therapeutic applications [17] [18] [19] [20] [21] [22] [23] [24] . The antiinflammatory potential of 2-styrylchromones, concerning their interference with the arachidonic acid metabolic pathways, has not been explored so far. However, this may represent a promising field of research considering the potent inhibition of eicosanoids production by certain flavonoids containing structural similarities with 2-SC (see [25] for review). Therefore, the purpose of this work was to evaluate the inhibition of COX-1 and COX-2 activities, in a cell-free system, as well as the inhibition of LTB 4 production, in human PMNL, by a group of 2-SC ( Fig. 2 ).
-Please place fig. 1 and fig. 2 here-M a n u s c r i p t 2-Styrylchromones 1A-1D, 2A-2D and 3A-3D were synthesised by the three step Baker-Venkataraman method, starting from the O-protected 2'-hydroxyacetophenones and cinnamoyl chlorides [26] . The first step involves the O-acylation of appropriate 2'-hydroxyacetophenones with cinnamoyl chloride derivatives to give 2'-cinnamoyloxyacetophenones. These intermediates were converted into 5-aryl-3-hydroxy-1-(2-hydroxyaryl)-2,4-pentadien-1-ones by the basecatalysed Baker-Venkataraman rearrangement [27] [28] [29] . The cyclodehydration of these βdiketones with a mixture of DMSO and a catalytic amount of iodine or p-toluenesulfonic acid gives polybenzyloxy-2-SC, which were debenzylated by treatment with hydrogen bromide in acetic acid at reflux, to give the expected hydroxy-2-SC 1A-1D, 2A-2D and 3A-3D.
Equipment
M a n u s c r i p t 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65   7 A microplate reader (Synergy HT, BIO-TEK), was used to perform the spectrophotometric readings in all the assays.
Determination of LTB 4 production by human PMNL
Human PMNL were isolated from peripheral blood of healthy volunteers as previously described [30] . Neutrophil suspensions (5 x 10 6 cells/mL) in HBSS were pre-incubated at 37ºC for 10 min with the 2-SC (25 and 10 µM) or with the lipoxygenase inhibitor, NDGA (1 µM). The cells were subsequently incubated with A23187 (5 µM) and arachidonic acid (10 µg/mL) for 8 min. The reactions were stopped by the addition of cold methanol. Samples were subsequently centrifuged at 13,000 x g for 1 min, and the supernatants were stored at -70ºC until analysis. The amount of LTB 4 in the samples was measured using the above mentioned commercial EIA kit, according to the manufacturer's instructions. The results were expressed as the percent inhibition of control LTB 4 production. At least four determinations were done for each experiment.
COX-1 and COX-2 inhibition assays
The inhibition of COX-1 (ovine) and COX-2 (human recombinant) by 2-SC was determined in a cell-free system by quantifying the levels of PGF 2α , produced by catalysis of arachidonic acid, using the above mentioned specific EIA kit according to the manufacturer's instructions.
The COX inhibitors indomethacin and celecoxib were used as positive controls. The results were expressed as the percent inhibition of control COX-1 or COX-2 activity. At least four determinations were done for each experiment.
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Determination of the reducing power
The reductive potential of 2-SC was determined according to a previously described method [31] . Test compounds, in 1 mL of a ultrapure water/DMSO 1:4 solution, were mixed with phosphate buffer (2.5 mL, 0.2 M, pH 6.6) and potassium ferricyanide [K 3 Fe(CN) 6 ] (2.5 mL, 1% w/v). The mixture was incubated at 50ºC for 20 min. A portion (2.5 mL) of trichloroacetic acid (10% w/v) was added to the mixture, which was then centrifuged for 10 min at 3000g. The upper layer of the solution (2.5 mL) was mixed with ultrapure water (2.5 mL) and FeCl 3 (0.5 mL, 0.1% w/v), and the absorbance was measured at 700 nm. Higher absorbance of the reaction mixture indicated greater reducing power. Ascorbic acid was used as standard compound.
Determination of metal chelating activity
The metal chelating activity was assessed by monitoring the changes in UV/Vis spectrum of 2-SC after addition of Fe(II) [32] . Titration experiments were performed by sequential additions of 2 µL of FeCl 2 solution (300 µM stock solution) to 300 µL of a 10 µM (final concentration) 2-SC solution. The titrations were performed in phosphate buffer 20 mM, pH 7.2.
Cytotoxicity 9
The effect of the 2-SC on the cell viability was assessed the trypan blue exclusion method and by the release of LDH (as a measure of cell membrane integrity). The LDH activity was determined by following the rate of oxidation of NADH at 340 nm.
Statistical analysis
Statistical analysis was performed by one-way analysis of variance (ANOVA) followed by Dunnett's multicomparison test using GraphPad Prism version 5.00 for Windows, GraphPad Software, San Diego California USA, www.graphpad.com". When comparing with control group, values of P less than 0.05 were considered significant.
Pearson correlation tests were performed using GraphPad Prism version 5.00 for Windows, GraphPad Software, San Diego California USA, www.graphpad.com".
Results

Inhibition of LTB 4 production by human PMNL
All the tested 2-SC showed to have inhibitory effects on the LTB 4 production by human PMNL. 2-SC from group 1 were more effective inhibitors of LTB 4 production than the correspondent compounds from the other groups. Compounds 1A, 1C, and 1D, at the concentration of 25 μM, were able to inhibit the LTB 4 production with a ≈ 90% effect, while the compound 1B showed a 66.0±12.4% effect at the same concentration ( Fig. 3) . These compounds were still very effective at the lowest tested concentration (10 μM), 1C being the strongest 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 10 inhibitor (80.9±10.1% effect, P<0.001) and 1B the weakest inhibitor (38.5±11.8% effect, P<0.01). 1A showed a 63.9±9.2% effect (P<0.001) and 1D showed a 62.3±7.9% effect (P<0.001). The compounds from group 2 were more effective inhibitors than the correspondent compounds from group 3. 2C was the most effective compound from group 2, reaching a 78.0±9.0% effect at the concentration of 25 μM, while 3D was the most effective compound from group 3, showing a 48.9±10.3% effect at the same concentration (Fig. 3) . These compounds were still significantly effective at the concentration of 10 μM, where 2C showed an effect of 50.6±11.9% (P<0.001) and 3D showed an effect of 42.2±9.6% (P<0.01). The compounds 1B, 2B, and 3B were the weakest inhibitors in the respective groups. The 5-LOX inhibitor NDGA (1 μM) reached a 76.1±11.0% inhibitory effect (Fig. 3 ). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 11 (92.6±2.1%) and the selective COX-2 inhibitor celecoxib (10 μM) could only inhibit this isoenzyme (68.2±3.0%).
-Please place fig. 4 here-
Reducing power
From the tested 2-SC, compounds 1A-1D and 2B were able to reduce, significantly, ferric ion.
Compounds from group 1 were shown to be more efficient reducers than ascorbic acid (Fig. 5 ).
-Please place fig. 5 here-
Metal chelating activity
The UV-Vis absorption spectrum of 2-SC 1A-1D shown a common absorption peak at 380 nm which presented bathochromic shift upon addition of growing amounts of Fe(II), increasing gradually until the 400 nm ( Fig. 6 ).
No relevant changes were observed in the UV-Vis spectrum of 2-SC from groups 2 and 3 upon addition of Fe(II). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65   12 
Cytotoxicity
None of the 2-SC caused an increased in the release of LDH compared to the control. The cell viability, assessed by the trypan blue exclusion method, was above 95% for all the compounds.
Correlations between the inhibition of LTB4 production and scavenging activity
Significant correlations were found between the inhibition of LTB 4 production, described in 3.1, and the scavenging activity for singlet oxygen ( 1 O 2 ), and peroxynitrite anion (ONOO -) (these assays were performed in a previous work [24] ). Table 1 here
Please place
Discussion
In this work, 2-SC were tested for their anti-inflammatory potential, through their capacity to interfere with the arachidonic acid metabolic pathways, in particular, the COX-1 and COX-2 pathways, studied in a cell-free system, and 5-LOX pathway, studied in a cellular system using human PMNL. All the studied compounds where shown to inhibit the LTB 4 production by human leukocytes, especially those with a catechol substituted B-ring. This biological effect of 2-SC is shown for the first time, in the present study. As previously mentioned, 2-SC are vinylogues of flavones. Accordingly, Yoshimoto et al. [33] had previously found that the flavone structure represents a pharmacophore for 5-LOX inhibitory activity. In a recent theoretical study 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 13 [34] , a correlation was found between the lipoxygenase inhibitory activity of flavonoid molecules and their planar character, which probably facilitates the access, through a hydrophobic cavity, to the catalytic site of the enzyme. Considering this rationale, the planar character of 2-SC [16, 29, 35] , conferred by the styryl link between the B-ring and the C-ring, may contribute to their [6, 25] . Accordingly, the reduction of ferric ion is a possible mechanism of inhibition of LTB 4 production by 2-SC, since the most effective compounds (1A-1D) also behaved as strong reducers (Fig. 3 vs. Fig. 5 ).
Indeed, significant correlation was found between the inhibition of LTB 4 production and the reducing power of the tested compounds (Table 1) . On the other hand, the spectral changes of those compounds upon addition of Fe(II) indicate the formation of iron complexes. The similar changes in all the compounds indicate that the Fe(II)-binding site is between the ortho-hydroxyl groups in the B-ring, considered to be one "iron binding motif" in flavonoid molecules [32, 36] . Furthermore, the Fe(II) titration curves reveal the formation of 1:2 Fe (II):compound complexes ( Fig. 6) . Besides indicating a possible mechanism of inhibition of LTB 4 production, the metal chelating capacity of the 2-SC from group 1, shown here for the first time, is also a very 14 important indicator of their antioxidant activity. Finally, the capacity of some 2-SC to scavenge reactive oxygen species (ROS) and reactive nitrogen species (RNS), demonstrated in a previous study [24] , is also likely to contribute to their LTB 4 production inhibitory effect. Noteworthy, significant correlations were found between the inhibition of LTB 4 production observed in the present study and the scavenging activity for singlet oxygen ( 1 O 2 ), and peroxynitrite anion (ONOO -) reported before (Table 1 ).
2-SC 1A, 1B, 1D and 2A where shown to significantly inhibit COX-1. This is also the first time that such biological activity of 2-SC is disclosed. On the other hand, none of the tested compounds was able to inhibit COX-2. Still, it is conceivable that this kind of effect might be seen at higher concentrations in accordance to what has been previously observed with a structural-similar compound (7,3',4'-trihydroxyflavone) [37] . However, due to solubility issues, the studied 2-SC could not be tested at higher concentrations. On the other hand, several flavonoids have previously shown to inhibit COX-2 expression (see [38] for review). The flavonoid's structural features considered by others [39] as relevant for this kind of activity are shared by some of the tested 2-SC, specifically compounds 1A and 2A. Thus, 2-SC, particularly the two referred compounds, may still be COX-2 inhibitors in vivo despite the negative results obtained in the present study.
The mechanism through which 2-SC inhibit COX-1 is likely to consist in the scavenging of the radical intermediates involved in COX enzyme catalysis, especially the phenoxy radical formed on a tyrosine residue, according to what has been previously suggested for other compounds with antioxidant moieties [40] . This mechanism is consistent with the fact that the only effective 2-SC where those which have shown higher ROS and RNS scavenging effects in our previous study [24] .
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The capacity of some of the tested 2-SC to inhibit both COX-1 and LOX pathways plays in favour of their potential use as effective and secure anti-inflammatory drugs, when compared to the commonly used NSAIDs and COXIBs. It is well known that NSAIDs may cause several adverse effects such as gastric ulceration, renal failure and asthma. On the other hand, the safety of selective COXIBs has been recently questioned due to the apparent association of these drugs with an increased risk of cardiovascular events. The cardiovascular adverse effects are probably due to a reduction on the levels of PGI 2 , an important anti-thrombotic eicosanoid, in concomitance to an excess of thromboxane A 2 , which has the opposite effect [41] [42] [43] .
Considering gastric effects, COX-2 selective inhibitors can delay the repair of existing gastrointestinal damage caused by ulcers, most likely by reducing the synthesis of PGs that are thought to play an important role in the healing process [44] . In fact, the inhibition of COX pathway has to be interpreted with careful because of the diversity of COX-derived mediators with different properties. Indeed, the PGE 2 , which has been mostly considered a proinflammatory mediator, has, on the other hand, given proves of involvement in anti-inflammatory and pro-resolving responses [45] [46] [47] . Furthermore, the COX inhibition shunts the arachidonic acid metabolism toward the 5-LOX pathway enhancing the gastric mucosal damages due to the augmented production of LTB 4 [44, 48] and inducing adverse reactions in patients with asthma as a result of the cys-LTs overgeneration [44] .
According to Bertolini et al. [14] , dual acting anti-inflammatory drugs may represent a breakthrough in the treatment of rheumatic diseases, in view of several important arguments: (i) the same molecule (i.e., one drug alone) inhibits both COXs and 5-LOX; (ii) the inhibition of both COX isoforms ensures a high anti-inflammatory efficacy and the concurrent preservation of the cardiovascular protective effects; (iii) the simultaneous inhibition of 5-LOX prevents pro- 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 16 inflammatory and gastrointestinal damaging effects of leukotrienes. From our point of view, the use of dual inhibitors of the COX/5-LOX pathways seems advantageous to the treatment of other inflammatory disorders beyond rheumatic diseases. In fact, this type of compounds may exhibit anti-inflammatory activity with a wider spectrum than that of classical NSAIDs by inhibiting 5-LOX product-mediated inflammatory reactions towards which NSAIDs are ineffective [44] .
Importantly, it has been demonstrated that the antioxidant effect of many NSAIDs may contribute to their therapeutic effectiveness [30, [49] [50] [51] . Thus, the strong antioxidant effects of 2-SC will certainly contribute to their anti-inflammatory efficacy in vivo.
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